Scholarlink

Purpose of Review <p>Urothelial carcinoma is a prevalent malignancy within the United States that may involve the upper and/or lower urinary tracts. Multimodal treatment is often employed, with transurethral resection and intravesical therapy standard of care for non-muscle-invasive disease; neoadjuvant systemic therapy followed by radical cystectomy or trimodal therapy for muscle-invasive disease; and combination immune checkpoint inhibitors and antibody-drug conjugates standard of care for metastatic disease. These treatments carry risks of surgical complication or treatment-associated toxicity which can impair quality of life. Predictive biomarkers of treatment tolerability are currently limited.</p> Recent Findings <p>There is emerging evidence that radiological biomarkers can predict treatment outcomes among patients with urothelial carcinoma.</p> Summary <p>In this review, we evaluate the existing data on radiological biomarkers evaluable from current standard-of-care imaging in predicting treatment outcome among patients with urothelial carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月21日

查看全文
  • Shelby Harper,
  • Erick M. Remer,
  • Nima Almassi

摘要

Purpose of Review

Urothelial carcinoma is a prevalent malignancy within the United States that may involve the upper and/or lower urinary tracts. Multimodal treatment is often employed, with transurethral resection and intravesical therapy standard of care for non-muscle-invasive disease; neoadjuvant systemic therapy followed by radical cystectomy or trimodal therapy for muscle-invasive disease; and combination immune checkpoint inhibitors and antibody-drug conjugates standard of care for metastatic disease. These treatments carry risks of surgical complication or treatment-associated toxicity which can impair quality of life. Predictive biomarkers of treatment tolerability are currently limited.

Recent Findings

There is emerging evidence that radiological biomarkers can predict treatment outcomes among patients with urothelial carcinoma.

Summary

In this review, we evaluate the existing data on radiological biomarkers evaluable from current standard-of-care imaging in predicting treatment outcome among patients with urothelial carcinoma.